[Doubleblind study with the novel antidepressant viloxazine versus imipramine in 50 in-patients (author's transl)].
In this double-blind study on 50 depressive patients viloxazine in dosages between 150-300 mg/die, showed to be a very active and well tolerated thymoleptic substance. Its profile of activity seems similar to that of imipramine. The differences in favour of viloxazine were: a more rapid onset of its effect, a more balanced stimulation of energetical level versus clearing up to depressed mood, evident better results in patients aged over 50, fewer drop-outs on account of complications (especially confusional states or psychotic symptom provocations) and fewer side-effects such as vegetative disfunction, vertigo, and weight increase. More initial fatigue reactions, slight sleep disturbances and 3 hypertensive transient reactions must be emphasized on the side of viloxazine.
D000928:Antidepressive Agents; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*
D000928:Antidepressive Agents; D009025:Morpholines; D007099:Imipramine
Doppelblindstudie mit dem neuen Antidepressivum Viloxazin im Vergleich zu Imipramin bei 50 stationäen Patientinnen